March 5, 2025 10:13 AM ESTUpdated 11:24 AM
News Briefing

Bris­tol My­er­s' MyoKar­dia unit ends work with Ful­crum; ALX dis­clos­es lay­offs

ENDPOINTS

Plus, news about Am­gen, Tenax Ther­a­peu­tics and Celon Phar­ma:

Ful­crum Ther­a­peu­tics los­es a part­ner: Bris­tol My­ers Squibb’s MyoKar­dia unit told Ful­crum …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Tome Bio founders wran­gle ‘jump­ing genes’ to cre­ate new pro­gram­ma­ble gene in­ser­tion tool

Re­cruiters say some bio­phar­mas pause hir­ing as they strug­gle to make sense of on­go­ing un­cer­tain­ty

FDA qui­et­ly be­gins re­vers­ing re­turn-to-of­fice man­date for some work­ers

Ira Mell­man joins PI­CI; Vi­iV Health­care CMO re­places Chris Cor­si­co at GSK

Biotech CEOs to Cas­sidy: We're al­ready see­ing the ef­fects of FDA's staff cuts

No­var­tis fol­lows Lil­ly and J&J in an­nounc­ing multi­bil­lion-dol­lar US man­u­fac­tur­ing in­vest­ment

A service from the Financial Times